top of page
DSC_2149_edited.jpg

Latest News

We help inventions grow!

Oct 16 2024

From the Lab to the Market: What Biotech Commercialization looks like from the Perspective of an Incubator

How does starting a company developing a new drug differ from, for example, one focused on IT? What can convince an investor to join such a company? Why should a scientist embark on the commercialization of their discoveries? What is the paradoxical advantage of being behind the global biotech leaders in the Czech Republic? And why do you sometimes feel like a translator? Jiří Moos, director of the biotech incubator i&i Prague, answers all these questions and much more in the following interview.

moos2.jpg

Oct 1 2024

PANC-CKI Consortium led by CasInvent pharma Secures €4M Eurostars Grant for Pancreatic Cancer Research

The PANC-CKI consortium, led by the Czech biotech, CasInvent Pharma, has been awarded a €4M Eurostars grant for a project entitled 'Developing a Novel Casein Kinase 1 Inhibitor for Pancreatic Cancer Treatment: An AI-Integrated Approach.' The project aims to validate CI-CK1i, a new inhibitor targeting casein kinase 1 (CK1) for the treatment of pancreatic cancer patient, needing urgently new treatment options.

Kamil Paruch with colleagues.jpg

Mar 11 2024

This fall Prague will be the stage for a showcase of cutting-edge biotechnologies featuring prominent figures such as Christian A. Stein, Petr Jansa, and other leading experts.

The capital city of the Czech Republic is set to host the second Prague.bio Conference on September 24th 2024. The event unites top minds in biotechnology, representatives from major investment funds, technology transfer law specialists and other professionals from the biotech and medtech sectors. For ticket purchases, the project registration form and the latest news visit: www.conference.prague.bio.

stein+jansa_edited.jpg

Nov 30, 2024

CasInvent Pharma raises € 1.6 million from i&i Prague and Other Investors to Support the Development of CK1 Inhibitors for Treatment-Resistant Solid and Hematological Tumours

CasInvent Pharma, a university spin-off focused on developing anti-cancer compounds, has successfully closed the Pre-Series A funding round, raising a total of € 1.6 million from both existing and new investors. Founded in 2020 as a spin-off from Masaryk University in Brno and with the support of i&i Prague, CasInvent Pharma specializes in the development of highly selective inhibitors targeting the casein kinase 1 enzyme family....

Kamil Paruch s kolegy 2a.jpg

Nov 30, 2023

IOCB Tech Group Successfully Represents the Czech Republic at the Prestigious Biotech Conference BIO-Europe 2023

Over 5,000 participants from more than 50 countries and a total of over 30,000 official meetings – that was the outcome of this year's edition of the international BIO-Europe conference in Munich. The Czech Republic was represented by the companies IOCB Tech, i&i Prague, and i&i Biotech Fund (i&i Bio)...

PHOTO-2023-11-07-18-32-21b.jpg

Apr 25, 2023

The Prague.bio international conference will bring together the best of science and business in Prague.

The first edition of the Prague.bio international conference will offer a unique meeting of representatives from science and business who will exchange their experiences in the development of new drugs, diagnostics, medical technologies and other areas of biotechnology. The event is supported by the Czech government and will feature renowned experts from the world of BioTech.

PragueBio_barva_RGB.png

Feb 7, 2023

New startup in our portfolio: Sophomer's technology will make immunoassays faster, easier and cheaper

The academic startup Sophomer today announced the signing of a licensing agreement to commercialize a technology that can replace the traditionally used bovine serum albumin (BSA) in immunoassays. The newly licensed technology has been developed in collaboration between the Institute of Macromolecular Chemistry of the CAS (IMC), Elisa Development and the bio-innovation center i&i Prague. The signing of the license agreement also officially accelerated the activities of the startup...

Sophomer.png

Feb 6, 2023

Czech liquid biopsy startup Elphogene comes under full control of one of the founders

Czech biotechnology start-up Elphogene who pioneered cancer monitoring through its liquid biopsy technology has announced a change in its shareholder structure. The new and sole owner is now Marek Minarik, one of the two original founders of the company. In the portfolio of the bio-innovation centre i&i Prague, Elphogene was one of the oldest startups. Now our mission is over.

elphogene - obdelnik.png

Dec 23, 2022

We are looking for new Antonin Holy and new drugs and diagnostics that can have a global impact and success

"i&i Bio invests in technology transfer with a strong focus on healthcare. We look for unique technologies that come from Czech and foreign science. We always try to find something new and unique, something that could bring great benefit to patients and also to our investors," says Jaromír Zahrádka for Fintag.cz. The podcast is in the Czech language.

sklo jaromir_mensi.jpg

i&i Prague Highlights

Other news

Interview with Jaromír Zahrádka: Investments help science to serve people
The judges at Transfera Technology Day 2021 awarded the cream of the crop
i&i Prague supports the innovative PEP-Therapy in their extension of the Series-A ...
Enantis concluded a license agreement for the production of stabilised growth factor FGF2
PerioTrap Pharmaceuticals Raises €3M Seed Round to Develop Selective  ...
Elphogene received a TA CR grant for “Sample prep system and technology for cancer ..." 
Our notes from a trip to “The most startup friendly country in the whole world”
Spin-off CasInvent Pharma receives the Neuron Award for excellent Technology Transfer
Licensing agreement for a novel SARS Cov-2 virus neutralization antibody test was signed
i&i Prague supported LAM-X a.s. won the 2020 EIT Health MedTech Bootcamp final ...
UCT Prague entered in memorandum with i&i Prague, s.r.o.
i&i Prague announces its first exit, DIANA Biotechnologies is bought out by its founders
i&i Bio, the newly estabilished investment fund powered by i&i Prague and EIF
Green chemistry start-up Sulfotools closes seed round with i&i Prague
CasInvent Pharma, an University Spin-Off Focused on Developing Cancer Drugs...
Dracen Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With ...
bottom of page